Skip to content

Ivacaftor

Cystic Fibrosis Transmembrane Conductance Regulator Potentiator — RESPIRATORY SYSTEM

Also known as: kalydeco, VX 770

OnpEMA approvedFDA approvedOrphan designationATC R07AX02ATC R07AX30ATC R07AX31

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Ivacaftor is an onp drug in the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Chloride Channel Activation Potentiators, Cytochrome P450 2C9 Inhibitors and Cytochrome P450 3A Inhibitors. DrugCentral lists 1 molecular target, including CFTR. Recorded indications include Cystic fibrosis of the lung.

  • Approval status: onp (first approved 2012 by the FDA).
  • Drug class: Cystic Fibrosis Transmembrane Conductance Regulator Potentiator.
  • Mechanism of action: Chloride Channel Activation Potentiators; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 3A Inhibitors.
  • Molecular targets: CFTR (1 listed in DrugCentral).
  • Indications: Cystic fibrosis of the lung.
  • ATC code: R07AX02 (Other respiratory system products).
  • Molecular formula: C24H28N2O3; molecular weight 392.50 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Cystic fibrosis of the lung

Mechanism & targets

Mechanism of action (MoA)Chloride Channel Activation Potentiators; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 3A Inhibitors; P-Glycoprotein Inhibitors
Established pharmacologic classCystic Fibrosis Transmembrane Conductance Regulator Potentiator

Molecular targets (1)

TargetGeneActionActivity
Cystic fibrosis transmembrane conductance regulatorCFTRotherEC50 8.52

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2020-08-21EMA—Vertex Pharmaceuticals (Ireland) LimitedYes
2012-01-31FDA—VERTEX PHARMSYes

ATC classification

ATC codeTherapeutic hierarchy
R07AX02RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Other respiratory system products
R07AX30RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Other respiratory system products
R07AX31RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Other respiratory system products
R07AX32RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Other respiratory system products

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label: CFTR · Testing Required
  • FDA label: CFTR · Testing Required
  • HCSC label: CFTR · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Infective pulmonary exacerbation of cystic fibrosis1869.1
Hospitalisation309.1
Pulmonary function test decreased149.2
Cystic fibrosis respiratory infection suppression124.7
Haemoptysis99.6
Amniotic fluid index increased95.0
Forced expiratory volume decreased94.8
Distal intestinal obstruction syndrome83.5
Left-to-right cardiac shunt80.1
Foetal macrosomia80.0
Alanine aminotransferase increased73.2
Abortion spontaneous69.9

Chemical structure

Molecular formulaC24H28N2O3
Molecular weight392.50 g/mol
CAS number873054-44-5
InChIKeyPURKAOJPTOLRMP-UHFFFAOYSA-N
PubChem CID16220172
CC(C)(C)C1=CC(=C(NC(=O)C2=CNC3=CC=CC=C3C2=O)C=C1O)C(C)(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ivacaftor used for?

DrugCentral lists the following indications for Ivacaftor: Cystic fibrosis of the lung.

How does Ivacaftor work?

Ivacaftor is classified as Chloride Channel Activation Potentiators, Cytochrome P450 2C9 Inhibitors and Cytochrome P450 3A Inhibitors; its molecular targets in DrugCentral include CFTR.

When was Ivacaftor first approved?

Ivacaftor was first approved by the FDA in 2012.

What drug class does Ivacaftor belong to?

Ivacaftor is in the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator class.

What is the chemical formula of Ivacaftor?

Ivacaftor has the molecular formula C24H28N2O3 and a molecular weight of 392.50 g/mol.

Browse: all drugs starting with I · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2012-01-31
AgencyFDA
Targets1
Indications1
FormulaC24H28N2O3
DrugCentral ID4228
Interactive profile